Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Progressive Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$8,739,919

1,680 payments

Through program year 2025, Progressive Clinical Research is reported as receiving $8,739,919 in research payments, across 1,680 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,013,510 222
2024 Research $1,001,780 438
2023 Research $1,377,019 332
2022 Research $1,518,367 200
2021 Research $1,304,533 122
2020 Research $1,105,854 203
2019 Research $1,418,856 163

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,944,628 52 payments
  2. Incyte Corporation $1,674,415 599 payments
  3. Ucb SA $588,959 35 payments
  4. Janssen Research & Development, LLC $575,967 98 payments
  5. Indivior Inc. $557,472 59 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $475,788 49 payments
  7. Genzyme Corporation $392,741 22 payments
  8. Novartis Pharmaceuticals Corporation $345,889 8 payments
  9. Pfizer Inc. $321,596 54 payments
  10. Bausch Health US, LLC $312,654 30 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomised, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended-Release Subcutaneous Injection (Rbp-6000) in Treatment-Seeking Adult Participants With Opioid Use Disorder and High-Risk Opioid Use $545,205 57 payments
  2. Activ-POC - AD - Topical $392,741 22 payments
  3. A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $339,526 3 payments
  4. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $288,216 4 payments
  5. Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis $272,789 5 payments
  6. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $261,378 4 payments
  7. A Study of Ly3454738 in the Treatment of Adult Participants With Moderate-To-Severe Atopic Dermatitis $247,585 3 payments
  8. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $245,105 29 payments
  9. A Phase 1B Open-Label, Randomized Study Evaluating the Safety and Systemic Pharmacokinetics of Topically Applied Idp-124 Lotion in Pediatric Subjects With Atopic Dermatiti $206,565 10 payments
  10. An Open Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis $196,544 56 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record